ISSWSH Guidelines on Hypoactive Sexual Desire Disorder
Low sexual desire in women has increasingly been recognized as a distinct clinical concern requiring formal diagnostic standards and structured medical care. In 2017, the International Society for the Study of Women's Sexual Health published an expert consensus panel review in Mayo Clinic Proceedings to provide clinicians with clear direction on evaluating and treating hypoactive sexual desire disorder. This guide breaks down the background, neurobiological frameworks, diagnostic thresholds, and therapeutic options described in that benchmark paper.
Background and Design of the ISSWSH Review
Hypoactive sexual desire disorder, commonly abbreviated as HSDD, is estimated to affect approximately 10% of adult women. To address disparities in clinical practice and consolidate emerging scientific insights, an expert panel formed by the International Society for the Study of Women's Sexual Health developed a comprehensive, evidence-based review. Published in the Mayo Clinic Proceedings expert consensus panel review, the document synthesized data spanning epidemiology, underlying physiology, pathogenesis, clinical diagnosis, and therapeutic management.
From a research design perspective, this publication represents a single expert consensus panel review rather than a primary randomized clinical trial. Its main function was to interpret available medical literature and formulate consensus recommendations for practicing health care providers. While consensus panels offer valuable synthesis from leading clinicians, they are inherently limited by the quality and scope of the published studies available at the time of evaluation.
Neurobiological Underpinnings: Central Excitation and Inhibition
A central contribution of the ISSWSH consensus document is its outline of the neurochemical mechanisms underlying female sexual motivation. The panel highlighted that sexual desire is modulated by an intricate balance between central excitatory and inhibitory pathways in the brain. According to the review, etiologic factors that suppress desire involve disruptions or medications that alter these neurochemical balances.
Specifically, the authors detailed that reduced desire can stem from conditions or pharmacological agents that decrease brain levels of:
- Dopamine
- Melanocortin
- Oxytocin
- Norepinephrine
Conversely, diminished desire is also linked to factors that augment central inhibitory signals. The panel identified increased brain levels of serotonin, endocannabinoids, prolactin, and opioids as drivers of decreased sexual interest. Recognizing these dual excitatory and inhibitory mechanisms has provided the rational framework for understanding how centrally acting desire drugs alter central neurochemistry.
Diagnostic Standards: The Timeline of Symptoms
Before any intervention can be considered, clinical guidelines establish rigorous diagnostic criteria to differentiate generalized clinical dysfunction from temporary fluctuations in desire. Under the ISSWSH consensus, an HSDD diagnosis requires a persistent lack or loss of motivation to engage in sexual activity.
Clinicians assess this loss across multiple specific manifestations:
- An absence or reduction of spontaneous sexual desire.
- A lack of responsive sexual desire triggered by erotic cues or external stimulation.
- An inability to maintain interest or desire throughout sexual encounters.
To meet diagnostic criteria, these symptoms must persist for at least 6 months and must be accompanied by clinically significant distress. The inclusion of personal distress is mandatory; low desire in the absence of distress does not qualify as a disorder under this clinical standard.
Clinical Management Within a Biopsychosocial Framework
The panel emphasized that managing HSDD requires a biopsychosocial model guided by thorough medical history taking and systematic symptom assessment. Addressing relationship dynamics, psychological factors, and lifestyle stressors serves as the foundation before or alongside pharmacotherapy.
Historically, sex therapy has served as the standard therapeutic intervention for women experiencing low sexual desire. However, the ISSWSH panel noted an important limitation in the literature: there is a recognized paucity of studies assessing the clinical efficacy of general sex therapy, with the notable exception of mindfulness-based cognitive behavior therapy, which possesses supporting evidence.
Medical Therapies and Prescription Guidelines
When psychological and behavioral approaches require medical support, clinicians reference specific pharmacological interventions identified in the Mayo Clinic Proceedings HSDD review. The authors noted that existing therapeutic agents share the hypothesized mechanism of altering central excitatory and inhibitory pathways.
The panel outlined the medical landscape as follows:
- Flibanserin: At the time of the review, flibanserin was identified as the only medication approved by the Food and Drug Administration specifically to treat premenopausal women with generalized acquired HSDD.
- Off-Label Testosterone: Menopausal women experiencing HSDD may benefit from off-label testosterone therapy. The panel cited evidence from multiple clinical trials demonstrating some efficacy and short-term safety in this demographic.
- Bupropion and Buspirone: These psychotropic agents may be considered as off-label therapeutic options for HSDD, though clinicians must weigh this choice against the limited safety and efficacy data documented in the literature.
Evidence Boundaries and Safety Cautions
While the ISSWSH consensus review confirmed that HSDD significantly impairs quality of life, the authors acknowledged critical evidence boundaries. Much of the clinical landscape relies on off-label prescribing, where high-level, long-term safety data remains constrained. Similarly, while testosterone demonstrated short-term safety for menopausal women in trials, long-term outcomes were not established within the cited evidence.
Because central pathways such as melanocortin receptors regulate desire, some individuals mistakenly look outside the medical system toward unapproved chemicals. Products like unregulated peptides sold online lack formal manufacturing controls, clinical trial safety oversight, or approved indications for sexual desire disorders. The panel's findings emphasize that sexual health concerns require legitimate clinical evaluation, accurate symptom tracking over time, and doctor-guided care tailored to an individual patient's health profile.
Sources
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.